ClinicalTrials.gg
CompletedNCT00887198Updated Feb 4, 2025Results posted

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 3 interventional study of Abiraterone acetate and Placebo in Prostate Cancer, sponsored by Janssen Research & Development, LLC. Completed at 135 sites in 11 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,088
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
5th of 98
1,088 · median 56
Started
2009
with 2 others
Phase 3
11 of 98
2 open now
Registered
8th of 98
by date
Lead sponsor
13 of 98
Janssen Research & Development, LLC

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 8th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).

Read the detailed description

This is a randomized (individuals will be assigned by chance to study treatments), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study in approximately 1,000 medically or surgically castrated male patients with metastatic CRPC who have shown tumor progression and are asymptomatic or mildly symptomatic. The study period will consist of screening, treatment, and follow-up phases. Patients will receive study treatment (abiraterone acetate or placebo) plus prednisone until radiographic progression of disease and/or unequivocal clinical progression. Efficacy evaluations will be performed throughout the treatment period and safety will be assessed until 30 days after the last dose of abiraterone acetate. throughout the study. Follow-up will continue for up to 60 months (5 years) or until the patient dies, is lost to follow-up, or withdraws informed consent. At the interim analysis of overall survival (OS; 43% of death events), the independent data monitoring committee (IDMC) reviewed the efficacy and safety data and concluded that all of the data pointed to a significant advantage for patients in one arm of the study compared with the other arm thereby unanimously recommending unblinding the study and allowing crossover from the placebo arm to active therapy. Patients currently receiving placebo will be offered crossover therapy to abiraterone acetate. Treatment for patients who were originally randomized to the abiraterone acetate treatment group will not change. Patients will be discontinued from long term follow-up at the time of the Clinical Cut-Off Date for Final Analysis (CCO-FA); however, patients still receiving treatment with abiraterone acetate at the CCO-FA will be offered to receive continued treatment for an additional period of up to 3 years or until disease progression or unacceptable toxicity. For these patients, safety assessment will be performed while continuing treatment, and for 30 days after the last dose of abiraterone acetate.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • Abiraterone acetate
  • CB7630
  • CRPC
  • Metastatic castration-resistant prostate cancer
  • hormone refractory prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • castration-resistant prostate cancer (CRPC)
  • Previous anti-androgen therapy and progression after withdrawal
  • performance status of either 0 or 1
  • Medical or surgical castration with testosterone less than 50 ng/dL
  • of at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Prior cytotoxic chemotherapy or biologic therapy for CRPC
  • Prior ketoconazole for prostate cancer
  • Known or visceral organ
  • Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,088 participants (actual)

Study arms

  • Placebo comparator
    Placebo + prednisone

    Placebo plus prednisone

    Drug: Placebo · Drug: Prednisone

  • Experimental
    Abiraterone + prednisone

    Abiraterone acetate plus prednisone

    Drug: Abiraterone acetate · Drug: Prednisone

Interventions

  • 1000 mg per day (4 x 250-mg tablets) taken orally.

  • DrugPlacebo

    4 placebo tablets per day taken orally.

  • 5 mg tablet orally twice daily.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as the time from randomization to date of death from any cause.

    Time frame: From randomization (Day 1) up to end of study (Month 60)

  2. Radiographic Progression-free Survival (rPFS)

    The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.

    Time frame: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)

Secondary outcomes

  1. Time to Opiate Use for Prostate Cancer Pain

    The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.

    Time frame: From randomization (Day 1) up to first opiate use or end of study (Month 60)

  2. Time to Initiation of Cytotoxic Chemotherapy

    The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.

    Time frame: From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)

  3. Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point

    The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.

    Time frame: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)

  4. Time to Prostate-specific Antigen (PSA) Progression

    The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.

    Time frame: From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)

  5. Number of Participants With Treatment Emergent Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: From first dose of study drug up to 30 days after the last dose of study drug

  6. Mean Plasma Concentrations of Abiraterone

    Time frame: Up to Cycle 5, Day 1

  7. Maximum Plasma Concentrations of Abiraterone

    Time frame: Up to Cycle 5, Day 1

  8. Area Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

    Time frame: Up to Cycle 5, Day 1

  9. Elimination Half-Life (t1/2)

    The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

    Time frame: Up to Cycle 5, Day 1

07

Results

Posted Apr 9, 2015

Participant flow

Randomized Period
Participant flow — Randomized Period
MilestoneAbiraterone Acetate + Prednisone (AAP)PlaceboPlacebo to AA
Started5465420
Treated5425400
Completed000
Not completed5465420
Withdrew: Ongoing4200
Withdrew: Adverse event50330
Withdrew: Lost to follow-up100
Withdrew: Cross-over to aa (under amendment 3)0510
Withdrew: Withdrawal by subject41560
Withdrew: Progressive disease3663700
Withdrew: Other42300
Withdrew: Randomized, not treated420
Cross Over (Placebo to AA)
Participant flow — Cross Over (Placebo to AA)
MilestoneAbiraterone Acetate + Prednisone (AAP)PlaceboPlacebo to AA
Started0093
Completed000
Not completed0093
Withdrew: Started other prostate cancer treatment008
Withdrew: Ongoing0035
Withdrew: Adverse event009
Withdrew: Withdrawal by subject002
Withdrew: Progressive disease0020
Withdrew: Other0019

Outcome measures

PrimaryOverall Survival

Overall survival is defined as the time from randomization to date of death from any cause.

Time frame:
From randomization (Day 1) up to end of study (Month 60)
Reported as:
Median · Months
Overall Survival
MonthsAbiraterone Acetate + Prednisone (AAP)Placebo
Overall Survival34.66 (32.72 to 36.80)30.29 (28.65 to 33.28)
PrimaryRadiographic Progression-free Survival (rPFS)

The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.

Time frame:
From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Reported as:
Median · Months
Radiographic Progression-free Survival (rPFS)
MonthsAbiraterone Acetate + Prednisone (AAP)Placebo
Radiographic Progression-free Survival (rPFS)NA (11.66 to NA)8.28 (8.12 to 8.54)
SecondaryTime to Opiate Use for Prostate Cancer Pain

The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.

Time frame:
From randomization (Day 1) up to first opiate use or end of study (Month 60)
Reported as:
Median · Months
Time to Opiate Use for Prostate Cancer Pain
MonthsAbiraterone Acetate + Prednisone (AAP)Placebo
Time to Opiate Use for Prostate Cancer Pain33.38 (30.23 to 39.75)23.39 (20.27 to 27.53)
SecondaryTime to Initiation of Cytotoxic Chemotherapy

The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.

Time frame:
From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)
Reported as:
Median · Months
Time to Initiation of Cytotoxic Chemotherapy
MonthsAbiraterone Acetate + Prednisone (AAP)Placebo
Time to Initiation of Cytotoxic Chemotherapy25.17 (23.26 to NA)16.82 (14.55 to 19.38)
SecondaryTime to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point

The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.

Time frame:
From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Reported as:
Median · Months
Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point
MonthsAbiraterone Acetate + Prednisone (AAP)Placebo
Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point12.29 (11.33 to 14.29)10.87 (9.49 to 11.76)
SecondaryTime to Prostate-specific Antigen (PSA) Progression

The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.

Time frame:
From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsAbiraterone Acetate + Prednisone (AAP)Placebo
Time to Prostate-specific Antigen (PSA) Progression11.07 (8.51 to 11.24)5.55 (5.39 to 5.59)
SecondaryNumber of Participants With Treatment Emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
From first dose of study drug up to 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsAbiraterone Acetate + Prednisone (AAP)PlaceboPlacebo to Abiraterone Acetate
With Treatment-Emergent Adverse Events54152493
With Treatment-Emergent Serious Adverse Events20814839
SecondaryMean Plasma Concentrations of Abiraterone
Time frame:
Up to Cycle 5, Day 1

No measurements were reported for this outcome.

SecondaryMaximum Plasma Concentrations of Abiraterone
Time frame:
Up to Cycle 5, Day 1

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])

The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

Time frame:
Up to Cycle 5, Day 1

No measurements were reported for this outcome.

SecondaryElimination Half-Life (t1/2)

The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

Time frame:
Up to Cycle 5, Day 1

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug up to 30 days after the last dose of study drug (Approximately 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Acetate + Prednisone (AAP)—215/542 (39.7%)530/542 (97.8%)
Placebo—156/540 (28.9%)505/540 (93.5%)
Placebo to AA—40/93 (43%)86/93 (92.5%)
Most frequent serious events
Showing 10 of 311
Most frequent serious events
EventAbiraterone Acetate + Prednisone (AAP)PlaceboPlacebo to AA
Disease ProgressionGeneral disorders8/5424/5406/93
Urinary Tract InfectionInfections and infestations14/5424/5405/93
HaematuriaRenal and urinary disorders11/5425/5403/93
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders10/54212/5401/93
FatigueGeneral disorders2/5420/5402/93
CellulitisInfections and infestations2/5423/5402/93
Myocardial InfarctionCardiac disorders4/5425/5402/93
Subdural HaematomaInjury, poisoning and procedural complications0/5422/5402/93
Pain in ExtremityMusculoskeletal and connective tissue disorders1/5421/5402/93
Calculus BladderRenal and urinary disorders0/5420/5402/93
Most frequent other events
Showing 10 of 54
Most frequent other events
EventAbiraterone Acetate + Prednisone (AAP)PlaceboPlacebo to AA
FatigueGeneral disorders243/542200/54027/93
Back PainMusculoskeletal and connective tissue disorders199/542180/54026/93
ArthralgiaMusculoskeletal and connective tissue disorders172/542131/54019/93
Oedema PeripheralGeneral disorders148/542119/54022/93
ConstipationGastrointestinal disorders144/542112/54015/93
NauseaGastrointestinal disorders144/542127/54015/93
Bone PainMusculoskeletal and connective tissue disorders144/542112/54014/93
DiarrhoeaGastrointestinal disorders135/54298/54013/93
HypertensionVascular disorders129/54273/5406/93
Hot FlushVascular disorders124/542100/5406/93

Baseline characteristics

Age, Continuous
Age, Continuous(years)Abiraterone Acetate + Prednisone (AAP)PlaceboTotal
Mean70.5 ± 8.870.1 ± 8.7270.3 ± 8.76
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone Acetate + Prednisone (AAP)PlaceboTotal
Female000
Male5465421088
Region of Enrollment
Region of Enrollment(Participants)Abiraterone Acetate + Prednisone (AAP)PlaceboTotal
Australia6072132
Belgium251742
Canada6337100
France242953
Germany463278
Greece7714
Italy167
Netherlands151530
Spain252045
Sweden41317
United Kingdom425698
United States234238472
08

Study locations

135 sites
  • Birmingham, Alabama, United States
  • Tucson, Arizona, United States
  • Bellflower, California, United States
  • Los Angeles, California, United States
  • Marina Del Rey, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Stanford, California, United States
  • Aurora, Colorado, United States
  • New Haven, Connecticut, United States
  • Boca Raton, Florida, United States
  • Fort Myers, Florida, United States
  • Gainesville, Florida, United States
  • Atlanta, Georgia, United States
  • Honolulu, Hawaii, United States
  • Kansas City, Kansas, United States
  • Metairie, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Dearborn, Michigan, United States
  • Saint Louis Park, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Billings, Montana, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • East Syracuse, New York, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Syracuse, New York, United States
  • Durham, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Canton, Ohio, United States
  • Cleveland, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Myrtle Beach, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Norfolk, Virginia, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • Adelaide, Australia
  • Camperdown, Australia
  • Footscray, Australia
  • Frankston, Australia
  • Garran, Australia
  • Geelong, Australia
  • Heidelberg, Australia
  • Herston, Australia
  • Hornsby, Australia
  • Kogarah, Australia
  • Kurralta Park, Australia
  • Lismore, Australia
  • Liverpool, Australia
  • Malvern, Australia
  • Parkville, Australia
  • Perth, Australia
  • South Brisbane, Australia
  • Southport, Australia
  • Subiaco, Australia
  • Aalst, Belgium
  • Antwerpen, Belgium
  • Gent, Belgium
  • Hasselt, Belgium
  • Leuven, Belgium
  • Roeselare, Belgium
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Kelowna, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Victoria, British Columbia, Canada
  • Hamilton, Ontario, Canada
  • London, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Quebec, Canada
  • Caen, France
  • Clichy, France
  • Dijon Cedex, France
  • La Roche sur Yon, France
  • Lyon Cedex 03, France
  • Lyon, France
  • Montpellier, France
  • Paris Cedex 15, France
  • Tours, France
  • Villejuif, France
  • Aachen, Germany
  • Berlin, Germany
  • Braunschweig, Germany
  • Dresden, Germany
  • Düsseldorf, Germany
  • Hamburg, Germany
  • Hannover, Germany

Showing the first 100 of 135 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lorente D, Llacer C, Lozano R, de Velasco G, Romero-Laorden N, Rodrigo M, Sanchez-Iglesias A, di Capua C, Castro E, Ferrer C, Sanchez-Hernandez A, Olmos D. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer. Eur Urol. 2021 Nov;80(5):641-649. doi: 10.1016/j.eururo.2021.07.014. Epub 2021 Aug 6. PubMed 34373138 ↗
  • Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Eur Urol. 2018 Jul;74(1):17-23. doi: 10.1016/j.eururo.2017.08.035. Epub 2017 Sep 20. PubMed 28939004 ↗
  • de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 Apr;71(4):656-664. doi: 10.1016/j.eururo.2016.06.033. Epub 2016 Jul 9. PubMed 27402060 ↗
  • Fizazi K, Flaig TW, Stockle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016 Apr;27(4):699-705. doi: 10.1093/annonc/mdv545. Epub 2015 Nov 25. PubMed 26609008 ↗
  • Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16. PubMed 25985882 ↗
  • Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res. 2015 Jul 15;21(14):3170-7. doi: 10.1158/1078-0432.CCR-14-1549. Epub 2015 Mar 31. PubMed 25829400 ↗
  • Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20;33(12):1356-63. doi: 10.1200/JCO.2014.55.3875. Epub 2015 Jan 26. PubMed 25624432 ↗
  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. PubMed 25601341 ↗
  • Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res. 2015 Apr 1;21(7):1621-7. doi: 10.1158/1078-0432.CCR-14-1961. Epub 2015 Jan 15. PubMed 25593303 ↗
  • Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct;12(5):e167-72. doi: 10.1016/j.clgc.2014.03.010. Epub 2014 Mar 28. PubMed 24787968 ↗
  • Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6. PubMed 24647231 ↗
  • Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1193-9. doi: 10.1016/S1470-2045(13)70424-8. Epub 2013 Sep 25. PubMed 24075621 ↗
  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. PubMed 23228172 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in Mar 2014, 59 months.

Results were first posted in Apr 2015, 1 year after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 59 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2009
First posted
Apr 23, 2009
StartActual
Apr 28, 2009
Primary completionActual
Mar 31, 2014
CompletionActual
May 25, 2017
Results first posted
Apr 9, 2015
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00887198
Responsible party
Sponsor
First posted
Apr 23, 2009
Start date
Apr 28, 2009
Primary completion
Mar 31, 2014
Completion
May 25, 2017
Results posted
Apr 9, 2015
Last update
Feb 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion